Precigen, Inc. P/S ratio

P/S ratio of PGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/S ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its sales per share. It is used by investors mainly because it’s less volatile than P/E and less subject to accounting manipulation. A low P/S ratio compare to historical average or other companies in the same industry might indicate undervaluation.


Highlights and Quick Summary

Current P/S ratio of Precigen, Inc. is 17.62 (as of December 30, 2020)
  • P/S ratio for the quarter ending June 29, 2021 was 12.85 (a -5.71% decrease compared to previous quarter)
  • Year-over-year quarterly P/S ratio increased by 123.62%
  • Annual P/S ratio for 2020 was 17.62 (a 89.24% increase from previous year)
  • Annual P/S ratio for 2019 was 9.31 (a 66.17% increase from previous year)
  • Annual P/S ratio for 2018 was 5.6 (a -23.92% decrease from previous year)
Visit stockrow.com/PGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/S ratio of Precigen, Inc.

Most recent P/S ratioof PGEN including historical data for past 10 years.

Interactive Chart of P/S ratio of Precigen, Inc.

Precigen, Inc. P/S ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 12.85 13.62
2020 17.62 5.74 8.57 5.56 17.62
2019 9.31 8.23 9.53 6.1 9.31
2018 5.6 11.47 9.07 9.38 5.6
2017 7.37 11.68 14.2 11.72 7.37
2016 15.33 17.79 15.24 21.62 15.33
2015 19.29 21.87 40.71 49.16 19.29
2014 37.96 38.68 75.71 92.28 37.96
2013 41.02 65.83 8.64 8.64 41.02
2012 8.64 8.64 8.64
2011 8.64

Business Profile of Precigen, Inc.

Sector: Healthcare
Industry: Biotechnology
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.